Open AccessClinical efficacy of low-dose emetine for patients with COVID-19: a real-world study
Author(s) -
Saijun Fan,
Qi Zhen,
Cheng Chen,
Wenjun Wang,
Qibing Wu,
Huihui Ma,
Chengyuan Zhang,
Li Zhang,
Benzhuo Lu,
Huiyao Ge,
Yong Liang,
Bao Li,
Yafen Yu,
Weiwei Chen,
Yan Mao,
Guangbo Qu,
Li Su,
Aoli Wang,
Ding Zhang,
Haiwen Li,
Jin Zhang,
Wang Yong-lian,
Yufeng Gao,
Xiuli Xu,
Zhongming Zhu,
Jun Chen,
Long Zhang,
Hongqiang Liang,
Song Wu,
Meng Huang,
Qing Xia,
Ping Li,
Yehuan Sun,
Chaozhao Liang,
Wei Wei,
Qingsong Liu,
Liangdan Sun
Publication year - 2020
Publication title -
journal of bio-x research/journal of bio-x research
Language(s) - English
Resource type - Journals
eISSN - 2096-5672
pISSN - 2577-3585
DOI - 10.1097/jbr.0000000000000076
Subject(s) - medicine , emetine , clinical trial , covid-19 , randomized controlled trial , adverse effect , disease , infectious disease (medical specialty) , pharmacology
Emetine, an isoquinoline alkaloid that is enriched at high concentrations in the lung, has shown potent in vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The aim of this study was to better understand the effectiveness of low-dose emetine for patients with coronavirus disease 2019 (COVID-19).